{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:32:59Z","timestamp":1788827579928,"version":"build-2803163510"},"reference-count":33,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen Canada"},{"name":"Princess Margaret Cancer Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Real-world evidence for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC) in Canada is limited. This study\u2019s objective was to use previously validated DARWENTM artificial intelligence (AI) to extract data from electronic heath records of patients with non-squamous NSCLC at University Health Network (UHN) to describe EGFR mutation prevalence, treatment patterns, and outcomes. Of 2154 patients with NSCLC, 613 had advanced disease. Of these, 136 (22%) had common sensitizing EGFR mutations (cEGFRm; ex19del, L858R), 8 (1%) had exon 20 insertions (ex20ins), and 338 (55%) had EGFR wild type. One-year overall survival (OS) (95% CI) for patients with cEGFRm, ex20ins, and EGFR wild type tumours was 88% (83, 94), 100% (100, 100), and 59% (53, 65), respectively. In total, 38% patients with ex20ins received experimental ex20ins targeting treatment as their first-line therapy. A total of 57 patients (36%) with cEGFRm received osimertinib as their first-line treatment, and 61 (39%) received it as their second-line treatment. One-year OS (95% CI) following the discontinuation of osimertinib was 35% (17, 75) post-first-line and 20% (9, 44) post-second-line. In this real-world AI-generated dataset, survival post-osimertinib was poor in patients with cEGFR mutations. Patients with ex20ins in this cohort had improved outcomes, possibly due to ex20ins targeting treatment, highlighting the need for more effective treatments for patients with advanced EGFRm NSCLC.<\/jats:p>","DOI":"10.3390\/curroncol31040146","type":"journal-article","created":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T03:37:21Z","timestamp":1712115441000},"page":"1947-1960","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Real-World Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence"],"prefix":"10.3390","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0821-5976","authenticated-orcid":false,"given":"Ruth","family":"Moulson","sequence":"first","affiliation":[{"name":"Pentavere, 460 College Street, Toronto, ON M6G 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Law","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Sacher","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances A.","family":"Shepherd","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Bradbury","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawson","family":"Eng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Iczkovitz","sequence":"additional","affiliation":[{"name":"Janssen Inc., Toronto, ON M3C 1L9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Abbie","sequence":"additional","affiliation":[{"name":"Janssen Inc., Toronto, ON M3C 1L9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Elia-Pacitti","sequence":"additional","affiliation":[{"name":"Janssen Inc., Toronto, ON M3C 1L9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel M.","family":"Ewara","sequence":"additional","affiliation":[{"name":"Janssen Inc., Toronto, ON M3C 1L9, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoriia","family":"Mokriak","sequence":"additional","affiliation":[{"name":"Pentavere, 460 College Street, Toronto, ON M6G 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Weiss","sequence":"additional","affiliation":[{"name":"Pentavere, 460 College Street, Toronto, ON M6G 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Pettengell","sequence":"additional","affiliation":[{"name":"Pentavere, 460 College Street, Toronto, ON M6G 1A1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha B.","family":"Leighl","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 2C1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"ref_1","unstructured":"Canadian Cancer Society (2023, August 26). Lung and Bronchus cancer Statistics. Available online: https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/lung\/statistics."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1916623","article-title":"The Effect of Advances in Lung-Cancer Treatment on Population Mortality","volume":"383","author":"Howlader","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_3","first-page":"25","article-title":"NSCLC: An Update of Driver Mutations, Their Role in Pathogenesis and Clinical Significance","volume":"98","author":"Black","year":"2015","journal-title":"R. I. Med. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal Growth Factor Receptor Mutations in Lung Cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic Driver Mutations in Non-Small Cell Lung Cancer: Past, Present and Future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3747\/co.25.3867","article-title":"Standardizing Biomarker Testing for Canadian Patients with Advanced Lung Cancer","volume":"25","author":"Melosky","year":"2018","journal-title":"Curr. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Burnett, H., Emich, H., Carroll, C., Stapleton, N., Mahadevia, P., and Li, T. (2021). Epidemiological and Clinical Burden of EGFR Exon 20 Insertion in Advanced Non-Small Cell Lung Cancer: A Systematic Literature Review. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0247620"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","article-title":"Metastatic Non-Small Cell Lung Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up","volume":"29","author":"Planchard","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","article-title":"Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/jclinpath-2012-201194","article-title":"EGFR Mutation Testing in Lung Cancer: A Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples","volume":"66","author":"Ellison","year":"2013","journal-title":"J. Clin. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S208","DOI":"10.1016\/j.jtho.2021.01.112","article-title":"FP07.12 Underdiagnosis of EGFR Exon 20 Insertion Mutation Variants: Estimates from NGS-Based Real-World Datasets","volume":"16","author":"Bauml","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3747\/co.26.4731","article-title":"A Canadian Guideline on the Use of Next-Generation Sequencing in Oncology","volume":"26","author":"Yip","year":"2019","journal-title":"Curr. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.3747\/co.27.6007","article-title":"Canadian Consensus: A New Systemic Treatment Algorithm for Advanced Egfr-Mutated Non-Small-Cell Lung Cancer","volume":"27","author":"Melosky","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"497","DOI":"10.6004\/jnccn.2022.0025","article-title":"Non\u2013Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Ettinger","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance Mechanisms to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13045-022-01391-4","article-title":"Therapeutic Strategies for EGFR-Mutated Non-Small Cell Lung Cancer Patients with Osimertinib Resistance","volume":"15","author":"Fu","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40801-022-00302-w","article-title":"Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data","volume":"9","author":"Nieva","year":"2022","journal-title":"Drugs Real World Outcomes"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102105","DOI":"10.1016\/j.ctrv.2020.102105","article-title":"EGFRExon 20 Insertions in Advanced Non-Small Cell Lung Cancer: A New History Begins","volume":"90","author":"Remon","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/ijc.30047","article-title":"NSCLC Harboring EGFR Exon-20 Insertions after the Regulatory C-Helix of Kinase Domain Responds Poorly to Known EGFR Inhibitors","volume":"139","author":"Yang","year":"2016","journal-title":"Int. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1016\/j.cllc.2019.06.018","article-title":"Effectiveness of Treatments for Advanced Non\u2013Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations","volume":"20","author":"Wu","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1056\/NEJMoa2306441","article-title":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","volume":"389","author":"Zhou","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_22","first-page":"100340","article-title":"Automating Access to Real-World Evidence","volume":"3","author":"Gauthier","year":"2022","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e33799","DOI":"10.2196\/33799","article-title":"Research and Application of Artificial Intelligence Based on Electronic Health Records of Patients With Cancer: Systematic Review","volume":"10","author":"Yang","year":"2022","journal-title":"JMIR Med. Inform."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jama.2018.18932","article-title":"Questions for Artificial Intelligence in Health Care","volume":"321","author":"Maddox","year":"2019","journal-title":"JAMA"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e18096","DOI":"10.1200\/JCO.2019.37.15_suppl.e18096","article-title":"Generating Real-World Evidence: Using Automated Data Extraction to Replace Manual Chart Review","volume":"37","author":"Law","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2200182","DOI":"10.1200\/CCI.22.00182","article-title":"Developing a Data and Analytics Platform to Enable a Breast Cancer Learning Health System at a Regional Cancer Center","volume":"7","author":"Petch","year":"2023","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_27","unstructured":"Vender, R., and Lynde, C. (2023, August 28). AI-Powered Patient Identification to Optimize Care. Canadian Dermatology Association. Available online: https:\/\/event.fourwaves.com\/cda2023\/abstracts."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e12575","DOI":"10.2196\/12575","article-title":"Extracting Clinical Features From Dictated Ambulatory Consult Notes Using a Commercially Available Natural Language Processing Tool: Pilot, Retrospective, Cross-Sectional Validation Study","volume":"7","author":"Petch","year":"2019","journal-title":"JMIR Med. Inform."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.1016\/j.jtho.2022.07.413","article-title":"EP04.01-001 Prevalence And Outcomes of EGFR Exon 20 Insertion Mutation In NSCLC: Princess Margaret Cancer Center Experience","volume":"17","author":"Mittal","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7198","DOI":"10.3390\/curroncol29100567","article-title":"Prevalence, Treatment Patterns, and Outcomes of Individuals with EGFR Positive Metastatic Non-Small Cell Lung Cancer in a Canadian Real-World Setting: A Comparison of Exon 19 Deletion, L858R, and Exon 20 Insertion EGFR Mutation Carriers","volume":"29","author":"Jarada","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.3390\/curroncol29070352","article-title":"Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer","volume":"29","author":"Kuang","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_32","first-page":"100433","article-title":"Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry","volume":"4","author":"Mountzios","year":"2023","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S1556-0864(23)00273-3","article-title":"19P\u2014Mortality Among EGFR-Mutated Advanced NSCLC Patients After Frontline Osimertinib Treatment: A Real-World, US Attrition Analysis","volume":"18","author":"Girard","year":"2023","journal-title":"J. Thorac. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/4\/146\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:22:41Z","timestamp":1760106161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/4\/146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":33,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["curroncol31040146"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31040146","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]}}}